INTRODUCTION
============

Transradial intervention (TRI) is known to be associated with fewer vascular complications and shorter duration of hospitalization than transfemoral intervention (TFI) \[[@b1-kjim-2016-316],[@b2-kjim-2016-316]\]. In previous studies, TFI is associated with up to 10% of incidence rate of bleeding and vascular complications \[[@b3-kjim-2016-316]\]. Primary percutaneous coronary intervention (PCI) for ST-elevation myocardial infarction (STEMI) is known to be associated with higher rates of bleeding complications, access site complications, and a need for transfusion in the TFI. These complications have been associated with poorer outcomes. They are also independent prognostic factors of mortality \[[@b4-kjim-2016-316]\]. Other complications including arteriovenous fistula (AVF), pseudoaneurysm (PSA), acute arterial occlusion, and infection can also influence mortality of STEMI patients \[[@b5-kjim-2016-316],[@b6-kjim-2016-316]\].

Recently, TRI is becoming more widely used for routine PCI with contemporary drug-eluting stents (DESs) due to several advantages, including less bleeding, less vascular complications, lower mortality, and early ambulation. In Radial Versus Femoral Access for Coronary Angiography or Intervention (RIVAL) study, the TRI approach has shown a significantly lower 30-day mortality \[[@b7-kjim-2016-316]\]. However, there has been limited published data regarding the clinical outcomes of TRI versus TFI in Korean patients with STEMI.

Therefore, the objective of this study was to compare in-hospital complications and major clinical outcomes of TRI with those of TFI in a series of Korean STEMI patients undergoing primary PCI and DESs with 12-month of follow-up.

METHODS
=======

TRI working group registry
--------------------------

The Korean TRI working group (TRI-WG) registry was performed at nine university hospitals. These hospitals have high-volume patients and facilities for primary PCI and on-site cardiac surgery. Data were collected at each site by trained study coordinators with a standardized case report form. The study protocol was approved by the Institutional Review Board from each site, all patients provided written informed consent. Standardized definitions were used for all patient-related variables and clinical diagnoses. The study protocol was approved by the Ethics Committee at each participating institution.

Study population
----------------

A total of 4,785 patients who underwent PCI from January to December 2009 were retrospectively enrolled in the TRI-WG registry. A total of 936 eligible STEMI patients who underwent primary PCI with DESs were enrolled, patients were excluded if they had any of the following conditions: cardiogenic shock on admission, Killips grade IV cardiac function, hemodynamic supporting devices (intra-aortic balloon counterpulsation or extracorporeal membrane oxygenation), received bare metal stents, or received balloon angioplasty. A total of 689 patients were finally enrolled for this study and divided into two groups according to vascular access (transradial approach group, n = 220; transfemoral approach group, n = 469). To adjust baseline potential confounders, propensity score matched (PSM) analysis was performed using logistic regression model. After PSM, two well-balanced and well-matched groups (171 pairs, n = 342, C-statistic = 0.792) were generated and analyzed.

PCI procedure and medical treatment
-----------------------------------

Diagnostic angiography and PCI were performed through either the femoral or radial artery after administration of unfractionated heparin (70 to 100 U/kg) to maintain activated clotting time of \> 250 seconds in patients during the procedure. Stents were deployed after balloon angioplasty. Cilostazol or platelet glycoprotein (GP) IIb/IIIa receptor blocker was used at the discretion of individual operator. A successful PCI was defined as the achievement of an angiographic residual stenosis of less than 30% in the presence of thrombolysis in myocardial infarction (TIMI) blood flow grade 3. During in-hospital period, patients received cardiovascular beneficial medications including β-blockers, renin angiotensin system inhibitors, calcium channel blockers, and statins. After discharge, patients were encouraged to stay on the same medications as they received in the hospital.

Study deﬁnitions and clinical follow-up
---------------------------------------

Cardiovascular risk factors and past history (age, sex, hypertension, dyslipidemia, smoking, diabetes mellitus, prior myocardial infarction \[MI\], chronic heart failure \[HF\], prior cerebrovascular disease, and peripheral arterial disease) were based on self-reports of patients. Assess site complications were defined as vascular complications that occurred in the access vessel such as hematomas (minor hematoma was defined as \< 4 cm of hematoma induration and major hematoma ≥ 4 cm), dissections, perforations, AVFs, and PSAs. Bleeding complications were defined as those previously described by Mehran et al. \[[@b8-kjim-2016-316]\]. Procedure times were measured from the start of the puncture to the removal of the guiding catheters. Fluoroscopy times were measured automatically using fluoroscopes. Clinical endpoints were defined as those previously described by Cutlip et al. \[[@b9-kjim-2016-316]\]. All deaths were considered as cardiac ones unless a non-cardiac cause was documented. Recurrent MI (Re-MI) was defined as recurrent symptoms of new ST-segment elevation or re-elevation of cardiac markers to a level of at least twice of the normal upper limit. Target lesion revascularization (TLR) was defined as an ischemia-induced PCI of the target lesion due to restenosis or re-occlusion within the stent or 5 mm in and adjacent of the distal or proximal segment. Target vessel revascularization (TVR) was defined as a clinically driven PCI of the target lesion or any segment of the coronary artery containing the target lesion. Total major adverse cardiac events (MACEs) was defined as the composite of total death, non-fatal Re-MI, and TVR. All participants were required to visit the outpatient Department of Cardiology at the end of the first month, every 3 to 6 months after the PCI procedure, and whenever angina-like symptoms occurred. Cumulative incidence of individual and composite clinical outcomes at 1-year of follow-up was compared between the two groups.

Study end-points
----------------

The primary study end-points were bleeding and vascular complications, procedural complications, and 30-day clinical outcomes after procedure. The secondary study end-points were cumulative incidence of individual and composite clinical outcomes during 1-year of clinical follow-up.

Statistical analysis
--------------------

For continuous variables, differences between the two groups were evaluated by unpaired t test or Mann-Whitney rank test. Data were expressed as mean ± standard deviation of means. For discrete variables, differences were expressed as counts and percentages. They were analyzed with chi-square or Fisher exact test between the two groups when appropriate. To adjust for potential confounders, PSM analysis was performed using logistic regression model. We tested all available variables that could be of potential relevance, including age, male, cardiovascular risk factors (hypertension, diabetes, dyslipidemia, HF, chronic kidney disease, coronary artery disease, stroke, peripheral artery disease, history of MI or PCI, and current smoker), angiographic factors (target vessels \[left main, left anterior descending, left circumflex, right coronary artery\], lesion type \[B2, C\], chronic total occlusion \[CTO\], bifurcation, diffuse long lesion, and calcification), and medications (cilostazol, angiotensin II receptor blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, β-blockers, diuretics, and statin). Patients in the TRI group were then 1-to-1 matched to those in the TFI group according to propensity scores with the nearest available pair matching method. Subjects were matched with a caliper width of 0.05. The procedure yielded 171 well-matched pairs. Cox-proportional hazard models were used to assess the hazard ratios in the two groups, the entire population, and the PSM population. The outcome of both groups were censored at a fixed point of 1 year (365 days) to avoid any bias caused by different follow-up duration. For all analyses, a two-sided *p* value of less than 0.05 was considered as statistically significant. All statistical analyses were performed using SPSS version 20.0 (IBM Co., Armonk, NY, USA).

RESULTS
=======

Baseline clinical characteristics and laboratory ﬁndings
--------------------------------------------------------

A total of 4,785 patients were enrolled in the Korean TRIWG registry, including 936 patients who were diagnosed with STEMI. Among the 936 patients, 247 patient did not fulfill the inclusion criteria. Finally, 220 patient underwent PCI via TRI group while 469 patients underwent PCI via TFI group ([Fig. 1](#f1-kjim-2016-316){ref-type="fig"}). The baseline demographics, clinical characteristics, and labora tory findings of the two groups are summarized in [Table 1](#t1-kjim-2016-316){ref-type="table"}. There were no significant differences in age, left ventricular ejection fraction, previous MI, or previous PCI. However, the prevalence rates of hypertension, diabetes, previous stroke, and current smoking were significantly higher than those in the TRI group. PSM yielded 171 pairs with well-balanced baseline characteristics. There was no significant differences in baseline characteristics between the TRI and TFI groups ([Table 1](#t1-kjim-2016-316){ref-type="table"}).

Baseline angiographic and procedural characteristics
----------------------------------------------------

At baseline angiography, the TFI group had higher incidence rates of multivessel disease, left circumflex lesion, B2/C lesions, and CTO lesion than the TRI group. The TFI group used bigger sheath than the TRI group. In addition, more patients in the TRI group used closure devices than those in the TRI group. Image and physiologic study guided intervention and adjuvant balloon inflation were more frequent in the TRI group compared to those in the TFI group. Baseline angiographic and procedural characteristics after PSM were similar to each other between the two groups except that the incidence rates of smaller sheath use, image and physiology guided intervention, and adjuvant ballooning were higher in the TRI group. Contrast amount was higher in the TRI group than that in the TFI group. Procedure time and fluoroscopic time were also longer in the TRI group ([Table 2](#t2-kjim-2016-316){ref-type="table"}).

Study primary end-points
------------------------

Major in-hospital and access site complications are listed in [Table 3](#t3-kjim-2016-316){ref-type="table"}. The incidence rates of procedure-related acute and in-hospital complications in the two groups were similar to each other. The incidence of vascular access site hematoma in the TFI group was significantly higher than that in the TRI group. Although the incidence of major hematoma was similar to each other between the two groups, the incidence of minor hematomas was higher in the TFI group than that in the TRI group. No major life-threatening bleeding complications were observed in either group. Furthermore, the incidence of anemia requiring transfusion was similar to each other between the two groups. After PSM, the incidence of minor hematoma remained more frequent in the TFI group. However, all other procedural and in-hospital complications were similar to each other between the two groups ([Table 3](#t3-kjim-2016-316){ref-type="table"}).

Study secondary end-points
--------------------------

In the entire patient population before PSM, the incidence rates of recurrent MI (particularly non-STEMI \[NSTEMI\]) and repeat revascularization including TLR and TVR were higher in the TFI group than those in the TRI group during the 12-month of follow-up. After PSM, the incident rates of major clinical outcomes including mortality, recurrent MI, TLR, and stent thrombosis rates during the 12-month of follow-up showed no disparity between the two groups. However, the incidence of TVR and MACE were higher in the TFI group ([Table 4](#t4-kjim-2016-316){ref-type="table"}).

Results of multivariate logistic regression analysis of individual and composite major clinical outcomes during the 12-month of follow-up are shown in [Table 5](#t5-kjim-2016-316){ref-type="table"}. The incident rates of TVR and MACE were higher in the TFI group after adjustment. In PSM patients, TRI strategy and adjuvant ballooning were independent predictors for lower incidence of repeat revascularization during the 12-month of follow-up ([Table 5](#t5-kjim-2016-316){ref-type="table"}).

DISCUSSION
==========

The main finding of the present study was that TRI for Korean STEMI patients undergoing a primary PCI with DES was associated with lower incidents of vascular access site complications, less in-hospital complications, less TVR, and less MACE in despite of longer procedure time and larger amount of contrast were needed during the 12-month of follow-up as compared to TFI.

The disadvantages of TRI include difficulty in learning the technique and a small radial artery size to work with. However, if the operator is experienced with routine TRI procedures in elective cases, TRI in acute myocardial infarction setting would be deemed safe and feasible. TRI can contribute to early ambulation and discharge \[[@b10-kjim-2016-316]\]. Delarche et al. \[[@b11-kjim-2016-316]\] have reported that TRI can be performed safely and effectively. Patients undergoing diagnostic cardiac catheterization are recommended to have transradial access because TRI can reduce hospital costs and improve the quality of life of patients after the procedure \[[@b12-kjim-2016-316]\]. Several studies have reported that TRI offers benefits to STEMI patients. However, no such benefit of TRI has been observed for patients with NSTEMI \[[@b13-kjim-2016-316]\]. The primary concern is the learning curve associated with TRI access \[[@b14-kjim-2016-316],[@b15-kjim-2016-316]\].

We have shown that even for an inexperienced TRI operator, the door-to-balloon and catheterization laboratory door-to-balloon times were acceptable at the outset. They were and improved significantly over the course of the study.

The success rates for the two groups were high. The proportions of patients with TIMI grade 3 flow at the end of the procedure were comparable between the two groups. In our study, the choice of the access site was entirely dependent on the operator. The presence of hemodynamic instability, arrhythmias at the time of STEMI diagnosis, and cardiogenic shock were not contraindicators for the transradial approach.

Since its introduction, TRI has gained more popularity due to its convenience and association with fewer complications \[[@b16-kjim-2016-316]\]. The RIVAL trial and a meta-analysis haves shown that TRI is associated with a significant reduction of vascular complications \[[@b7-kjim-2016-316]\]. Coronary stenting through the femoral route in acute coronary syndrome (ACS) is associated with more vascular complications. These complications are predictors of higher morbidity, longer hospital stays, and higher hospital costs \[[@b17-kjim-2016-316],[@b18-kjim-2016-316]\]. In ST-Segment Elevation Myocardial Infarction Treated by Radial or Femoral Approach in a Multicenter Randomized Clinical (STEMI-RADIAL) trial, radial access is associated with a superior net clinical benefit and less vascular complications than femoral access \[[@b19-kjim-2016-316]\]. With a trend toward a shorter length of hospitalization and fewer vascular complications, TRI appears to be more effective than TFI. The door-to-balloon time is shorter with the femoral approach. The choice of sheath is less restrictive with this approach. In addition, vascular closure devices can yield better clinical outcomes \[[@b7-kjim-2016-316],[@b14-kjim-2016-316]\]. A meta-analysis has shown that closure devices may reduce bleeding complications and mortality; thereby, filling the gap between the two access sites \[[@b15-kjim-2016-316]\].

It should be kept in mind that current literatures supporting radial access over femoral access have been reduced from studies involving suboptimal use of antithrombotic agents and unrestricted use of parenteral antiplatelet agents. Hence, a randomized study involving patients treated with bivalirudin or newer antiplatelets, and an appropriate use of anticoagulation regimens without adjunctive GP inhibitors is needed to determine access site advantage in STEMI patient.

In our study, even though the two groups showed no difference regarding in-hospital complications or mortality, local vascular complications and hematoma occurred solely in the TFI group, irrespective of whether a closure device was used. The incidence rates of access site complications and bleeding complications were significantly lower in the TRI group. In our study, higher loading dose of clopidogrel and use of a larger sheath were observed in the TFI group. Access site complications showed higher incidence of minor hematoma in the TFI group, which was belong to anatomical specificities in the TFI group treated with larger sheath, but this was not a serious complication affecting the major clinical outcomes including mortality rate. The device size and diameter used in the TFI procedure were significantly reduced and the performance of closure devices was more improved compared to the past. Thus, we think anatomic specificities between TFI and TRI did not reach in differences in major bleeding. However, exposure to radiation was higher in the TRI group than that in the TFI group in the RIVAL study, although the difference was only observed in low volume centers and operators \[[@b20-kjim-2016-316]\] consistent with our study results showing that contrast amount in the TRI group was higher while procedure time and fluoroscopic time were longer in the TRI group than those in the TFI group.

Previous study have shown that the crossover rate from TRI to TFI access is approximately 9.8% \[[@b14-kjim-2016-316]\]. Our crossover rate was 10%. This might reflect the initial limited experience of TRI operators as there was no more crossover during the last 12 months of the study.

The RIVAL trial results (published while our study was still in progress) showed that the primary outcomes of death, MI, stroke, and non-coronary artery bypass grafting bleeding were not significantly different between the two groups in the ACS population. However, in the subset of STEMI population, mortality rate was lower in the radial group compared to that in the femoral group. In Radial versus Femoral Randomized Investigation in ST-segment Elevation Acute Coronary Syndrome (RIFLE-STEACS) study, the radial approach reduced the rate of primary outcomes of cardiac death, stroke, MI, TLR, and bleeding during a 30-day follow-up compared to the femoral approach (13.6% vs. 21.0%, *p* = 0.003) and MACE \[[@b14-kjim-2016-316]\]. In our study, despite the two groups had similar incidence of mortality, the incidence of TVR and MACE were lower in the TRI group compared to those in the TFI group during the 12-month of follow-up. Although the baseline differences including multivessel diseases and CTO lesions were adjusted by PSM, still the TVR rate was lower in the TRI group than in the TFI group. The complex lesion subset and complex patients in the TFI group might not be perfectly adjusted by statistics because this result is not a randomized data. Furthermore, image-guided PCI was more frequently performed in the TRI group. We speculated that a higher incidence of image-guided PCI in the TRI group might lead to a higher incidence of subsequent adjuvant ballooning based on imaging findings to achieve stent optimization; thus, reducing the number of cases/episodes of stent malapposition and subsequent repeat revascularization. We think that the choice of TRI and TFI route was based on the individual operator's discretion and it did not have a direct impact on the outcome difference in our study.

In this study, TLR was included in the definition of TVR, and TLR also showed numerically lower in the TRI group although the difference was not statistically significant. In entire patients before PSM, the incidence of repeat revascularization including TLR and TVR was higher in the TFI group when compared with the TRI group during the 12-month follow-up. However, after the PSM analysis, the incidence of recurrent MI and TLR was similar between the two groups.

Instead of non-TVR, TVR difference is also important as TLR because the definition of TVR includes both TLR and non-TLR TVR. The TVR incidence includes in-stent, in-segment for both stent edges and non-target lesion progression. Thus, TVR is also an important component of repeat revascularization and should be interpreted as a major component of MACE. Our clinical endpoints are primarily focused on patient-based clinical outcomes rather than lesion-based clinical outcomes such as target-lesion failure.

The incidence of MACE was significantly lower in the TRI group than that in the TFI group mainly due to significantly lower incidence of TVR in the TRI group compared to that in the TFI group.

The present study has certain limitations. It was a retrospective observational study. Therefore, results must be interpreted with caution as technical differences among operators in different PCI centers might have caused biases. In addition, the in-hospital outcome results might have limitation since factors such as bleeding score was not recorded in the data due to the fact that this was a multicenter study without scheduled prospective protocol. Although the number of participants was relatively small to reach a definite final conclusion, radial access was found to have definite advantage in this study as in previous studies. This is clinically important implications for Korean population. Even though PSM was performed to eliminate biases, some unmeasurable confounders might have influenced the outcomes of the study.

In conclusion, TRI in STEMI patients undergoing primary PCI with DESs was associated with lower incidence of vascular-access site hematomas, lower 12-month TVR, and lower incidence of MACE despite of longer procedure time and larger amount of contrast needed in our study. There was no significant difference in in-hospital or 12-month mortality rate between the two groups. Our results suggest that TRI might play an important role in reducing access site vascular complications and improving mid-term major clinical outcomes in STEMI patients undergoing primary PCI with DES in Korean population.

KEY MESSAGE
===========

1\. Transradial intervention (TRI) in ST-elevation myocardial infarction patients undergoing primary percutaneous coronary intervention was associated with lower incidence of access site hematoma, 12-month repeat revascularization, and major adverse cardiac event compared to transfemoral intervention.

2\. TRI in acute myocardial infarction setting would be deemed safe and feasible.

3\. TRI can contribute to early ambulation and discharge.
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###### 

Baseline clinical characteristics and laboratory findings

  Characteristic                 Entire patients   Matched patients                                          
  ------------------------------ ----------------- ------------------ ---------- ------------- ------------- -------
  Male sex                       182 (82.7)        359 (76.5)         0.065      140 (81.8)    140 (81.8)    NS
  Age, yr                        62.7 ± 12.2       61.8 ± 12.4        0.432      61.9 ± 12.4   62.9 ± 12.0   0.399
  LV ejection fraction, %                                                                                    
   Before procedure              50.3 ± 9.5        50.6 ± 10.1        0.804      50.0 ± 9.5    51.7 ± 10.7   0.250
   After procedure               51.2 ± 10.3       52.1 ± 11.1        0.300      51.1 ± 9.9    52.1 ± 10.2   0.344
  Past history                                                                                               
   Hypertension                  113 (51.3)        165 (35.1)         \< 0.001   81 (47.3)     83 (48.5)     0.829
   Diabetes                      59 (26.8)         85 (18.1)          0.009      40 (23.3)     37 (21.6)     0.698
   Dyslipidemia                  57 (25.9)         103 (21.9)         0.253      45 (26.3)     46 (26.9)     0.903
   Stroke                        17 (7.7)          14 (2.9)           0.005      12 (7.0)      11 (6.4)      0.829
   Heart failure                 4 (1.8)           8 (1.7)            NS         3 (1.7)       4 (2.3)       NS
   Peripheral artery disease     3 (1.3)           1 (0.2)            0.098      1 (0.5)       1 (0.5)       NS
   Chronic kidney disease        4 (1.8)           8 (1.7)            NS         2 (1.1)       2 (1.1)       NS
   History of smoking            143 (65.0)        202 (43.0)         \< 0.001   109 (63.7)    104 (60.8)    0.577
   Current smokers               115 (52.2)        169 (36.0)         \< 0.001   87 (50.8)     84 (49.1)     0.746
   Prior myocardial infarction   9 (4.0)           10 (2.1)           0.143      5 (2.9)       3 (1.7)       0.723
   Prior PCI                     12 (5.4)          18 (3.8)           0.332      8 (4.6)       10 (5.8)      0.628
  Laboratory findings                                                                                        
   Hemoglobin, mg/dL             14.3 ± 1.8        14.1 ± 1.8         0.144      14.3 ± 1.8    14.1 ± 1.9    0.377
   CK-MB, mg/dL                  64 ± 181          43 ± 95            0.889                    27 ± 59       0.105
   Troponin T, ng/dL             1.0 ± 2.6         1.0 ± 2.4          0.247      1.2 ± 3.0     1.2 ± 2.5     0.454
   Creatinine, mg/dL             0.9 ± 0.3         1.0 ± 0.5          0.750      0.9 ± 0.2     0.9 ± 0.3     0.788
   Total cholesterol, mg/dL      179 ± 44          182 ± 40           0.263      178 ± 44      180 ± 36      0.735
   Triglyceride, mg/dL           121 ± 85          115 ± 87           0.108      119 ± 84      115 ± 81      0.510
   HDL-C, mg/dL                  40 ± 11           40 ± 9             0.657      41 ± 11       39 ± 8        0.510
   LDL-C, mg/dL                  113 ± 36          117 ± 35           0.256      113 ± 38      115 ± 33      0.693
   Serum glucose, mg/dL          160 ± 64          169 ± 68           0.100      159 ± 65      171 ± 72      0.046
   Hemoglobin A1c, %             6.4 ± 1.3         6.5 ± 1.5          0.660      6.4 ± 1.2     6.6 ± 1.7     0.441

Values are presented as number (%) or mean ± SD.

NS, not significant (\> 0.999); LV, left ventricle; PCI, percutaneous coronary intervention; CK-MB, creatine kinase-MB; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.

###### 

Baseline angiographic and procedural characteristics

  Characteristic                      Entire patients   Matched patients                                                
  ----------------------------------- ----------------- ------------------ ---------- ---------------- ---------------- ----------
  Multi-vessel disease                31 (14.0)         130 (27.7)         \< 0.001   28 (16.3)        31 (18.1)        0.668
   No. of treat vessels               1.3 ± 0.6         1.4 ± 0.6          0.054      1.3 ± 0.6        1.2 ± 0.4        0.816
  Target lesion                                                                                                         
   LAD                                134 (60.9)        290 (61.8)         0.816      106 (61.9)       113 (66)         0.430
   LCX                                22 (10.0)         82 (17.4)          0.011      21 (12.2)        11 (6.4)         0.063
   RCA                                94 (42.7)         222 (47.3)         0.258      71 (41.5)        73 (42.6)        0.827
   Left main                          2 (0.9)           12 (2.5)           0.245      2 (1.1)          3 (1.7)          NS
   Ramus                              2 (0.9)           1 (0.2)            0.240      1 (0.5)          1 (0.5)          NS
  Location                                                                 0.841                                        0.144
   Ostium                             125 (56.8)        273 (58.2)                    96 (56.1)        107 (62.5)       
   Proximal                           61 (27.7)         130 (27.7)                    47 (27.4)        49 (28.6)        
   Mid                                28 (12.7)         58 (12.3)                     23 (13.4)        14 (8.1)         
   Distal                             6 (2.7)           8 (1.7)                       5 (2.9)          1 (0.5)          
  Lesion characteristics                                                                                                
   Type (B2/C)                        165 (75.0)        435 (92.7)         \< 0.001   142 (83.0)       144 (84.2)       0.770
   Bifurcation                        44 (20.0)         118 (25.1)         0.136      35 (20.4)        37 (21.6)        0.791
   Diffuse (\> 20 mm)                 77 (35.0)         184 (39.2)         0.286      61 (35.6)        64 (37.4)        0.736
   Calcification                      25 (11.3)         32 (6.8)           0.044      21 (12.2)        21 (12.2)        NS
   Chronic total occlusion            30 (13.6)         37 (7.8)           0.018      23 (13.4)        25 (14.6)        0.756
  Stent type                                                                                                            
   Sirolimus-eluting                  10 (4.5)          58 (12.3)          0.001      9 (5.2)          14 (8.1)         0.280
   Paclitaxel-eluting                 85 (38.6)         188 (40.0)         0.717      66 (38.5)        68 (39.7)        0.825
   Zotarolimus-eluting                93 (42.2)         167 (35.6)         0.092      77 (45.0)        69 (40.3)        0.382
   Everolimus-eluting                 82 (37.2)         177 (37.7)         0.906      61 (35.6)        61 (35.6)        NS
  Procedural characteristics                                                                                            
   Sheath size, Fr                    5.9 ± 0.3         6.8 ± 0.3          \< 0.001   5.9 ± 0.3        6.8 ± 0.3        \< 0.001
   Use of closing devices             0                 223 (47.5)         \< 0.001   0                57 (33.3)        \< 0.001
   Image and FFR guided               110 (50.0)        54 (11.5)          \< 0.001   83 (48.5)        25 (14.6)        \< 0.001
    IVUS                              91 (41.3)         45 (9.5)           \< 0.001   67 (39.1)        23 (13.4)        \< 0.001
    FFR                               20 (9.0)          9 (1.9)            \< 0.001   17 (9.9)         2 (1.1)          \< 0.001
   Adjuvant balloon inflation         163 (74.0)        213 (45.4)         \< 0.001   131 (76.6)       70 (40.9)        \< 0.001
   Pre-loading of clopidogrel         206 (93.6)        455 (97.0)         0.036      159 (92.9)       166 (97.0)       0.082
   Loading dose, mg                   600 (300--600)    600 (450--600)     0.002      600 (300--600)   600 (600--600)   0.003
   High-loading (\> 300 mg)           136 (61.8)        279 (59.4)         0.560      103 (60.2)       123 (71.9)       0.022
   Pre-loading of cilostazol          13 (5.9)          40 (8.5)           0.229      10 (5.8)         14 (8.1)         0.397
   Low molecular weight heparin       37 (16.8)         60 (12.7)          0.157      29 (16.9)        25 (14.6)        0.553
   Glycoprotein IIb/IIIa inhibitors   44 (20.0)         100 (21.3)         0.691      34 (19.8)        43 (25.1)        0.244
   Contrast volume, cc                225.6 ± 82.8      220.8 ± 84.3       0.782      237.9 ± 87.9     216.1 ± 95.0     0.048
   Procedure time, min                41 (31--55)       35 (25--50)        \< 0.001   43 (31--55)      40 (25--50)      0.003
   Fluoroscopic time, min             12 (9--19)        10 (6--15)         0.003      13 (9--20)       10 (7--16)       0.019

Values are presented as number (%), mean ± SD, or median (interquartile range).

LAD, left anterior descending; LCX, left circumflex; RCA, right coronary artery; NS, not significant (\> 0.999); FFR, fractional flow reserve; IVUS, intravascular ultrasound.

###### 

Primary end-points: complications and cumulative 30-day clinical outcomes

  Variable                          Entire patients   Matched patients                                   
  --------------------------------- ----------------- ------------------ ------- ----------- ----------- -------
  Procedural complications          35 (15.9)         65 (13.8)          0.476   25 (14.6)   26 (15.2)   0.879
   Dissection                       2 (0.9)           14 (2.9)           0.092   1 (0.5)     5 (2.9)     0.215
   Perforation                      2 (0.9)           2 (0.4)            0.596   1 (0.5)     1 (0.5)     NS
   Acute thrombosis                 2 (0.9)           3 (0.6)            0.657   2 (1.1)     2 (1.1)     NS
   Distal embolization              2 (0.9)           2 (0.4)            0.596   1 (0.5)     2 (1.1)     NS
   No reflow                        16 (7.2)          27 (5.7)           0.443   11 (6.4)    10 (5.8)    0.822
   Side branch occlusion            11 (5.0)          15 (3.1)           0.247   9 (5.2)     5 (2.9)     0.275
  Access site complications                                                                              
   Dissection                       0                 1 (0.2)            NS      0           1 (0.5)     NS
   Hematoma                         0                 17 (3.6)           0.004   0           8 (4.6)     0.007
    Major (≥ 4 cm)                  0                 3 (0.6)            0.555   0           2 (1.1)     0.499
    Minor (\< 4 cm)                 0                 14 (2.9)           0.007   0           6 (3.5)     0.030
  In-hospital complications                                                                              
   Cardiogenic shock                6 (2.7)           12 (2.5)           0.897   4 (2.3)     4 (2.3)     NS
   Acute renal failure              2 (0.9)           2 (0.4)            0.596   1 (0.5)     0 (0.0)     NS
   Acute heart failure              2 (0.9)           5 (1.0)            NS      1 (0.5)     2 (1.1)     NS
   Stroke                           1 (0.4)           3 (0.6)            NS      1 (0.5)     1 (0.5)     NS
   Gastrointestinal bleeding        1 (0.4)           1 (0.2)            0.537   1 (0.5)     0           NS
   Transfusion                      6 (2.7)           19 (4.0)           0.386   3 (1.7)     7 (4.0)     0.199
   Transfusion (Pint)               3.3 ± 2.1         4.4 ± 7.5          0.623   3.3 ± 1.1   3.0 ± 3.1   0.197
   Contrast reaction                7 (3.1)           6 (1.2)            0.129   3 (1.7)     1 (0.5)     0.623
   Contrast induced nephropathy     6 (2.7)           4 (0.8)            0.082   2 (1.1)     1 (0.5)     NS
  30-Day outcomes after procedure                                                                        
   Total death                      6 (2.7)           10 (2.1)           0.629   4 (2.3)     2 (1.1)     0.685
    Cardiac death                   4 (1.8)           9 (1.9)            NS      2 (1.1)     2 (1.1)     NS
   Recurrent MI                     0                 3 (0.6)            0.555   0           1 (0.5)     NS
    NSTEMI                          0                 3 (0.6)            0.555   0           1 (0.5)     NS
   Revascularizations               0                 6 (1.2)            0.184   0           2 (1.1)     0.499
    Target lesion                   0                 6 (1.2)            0.184   0           2 (1.1)     0.499
    Target vessel                   0                 6 (1.2)            0.184   0           2 (1.1)     0.499
   Stent thrombosis                 0                 5 (1.0)            0.183   \-          \-          \-

Values are presented as number (%) or mean ± SD.

NS, not significant (\> 0.999); MI, myocardial infarction; NSTEMI, non-ST segment elevation MI.

###### 

Secondary end-points: cumulative 1-year major clinical outcomes

  Variable             Entire patients   Matched patients                                 
  -------------------- ----------------- ------------------ ------- --------- ----------- -------
  Total death          11 (5.0)          17 (3.6)           0.394   7 (4.0)   6 (3.5)     0.777
   Cardiac death       4 (1.8)           12 (2.5)           0.547   2 (1.1)   4 (2.3)     0.685
  Recurrent MI         0                 12 (2.5)           0.012   0         4 (2.3)     0.123
   STEMI               0                 2 (0.4)            NS      0         1 (0.5)     NS
   NSTEMI              0                 10 (2.1)           0.035   0         3 (1.7)     0.248
  Revascularizations   2 (0.9)           25 (5.3)           0.005   1 (0.5)   11 (6.4)    0.003
   Target lesion       2 (0.9)           17 (3.6)           0.042   1 (0.5)   6 (3.5)     0.121
   Target vessel       2 (0.9)           25 (5.3)           0.005   1 (0.5)   11 (6.4)    0.003
  Stent thrombosis     0                 6 (1.2)            0.184   0         1 (0.5)     NS
  Stoke                0                 2 (0.4)            NS      0         2 (1.1)     0.499
  MACE                 13 (5.9)          45 (9.5)           0.104   8 (4.6)   20 (11.6)   0.018

Values are presented as number (%). Univariate Cox proportional hazard analysis.

MI, myocardial infarction; STEMI, ST segment elevation MI; NS, not significant (\> 0.999); NSTEMI, non-STEMI; MACE, major adverse cardiac event.

###### 

Hazard ratio of transradial intervention for 12-month cumulative clinical outcomes compared with transfemoral intervention

  Variable             Entire patients     Matched patients                       
  -------------------- ------------------- ------------------ ------------------- -------
  Total death          1.50 (0.70--3.20)   0.294              1.28 (0.43--3.83)   0.648
   Cardiac death       0.76 (0.24--2.35)   0.636              0.54 (0.09--2.97)   0.484
  Recurrent MI         0.02 (0.00--5.46)   0.185              0.01 (0.00--52.4)   0.319
  Revascularizations   0.18 (0.04--0.79)   0.023              0.09 (0.01--0.75)   0.026
   Target lesion       0.27 (0.06--1.18)   0.084              0.17 (0.02--1.48)   0.111
   Target vessel       0.18 (0.04--0.79)   0.023              0.09 (0.01--0.76)   0.026
  MACE                 0.66 (0.35--1.23)   0.197              0.42 (0.18--0.96)   0.042

Univariate Cox proportional hazard analysis.

CI, confidence interval; MI, myocardial infarction; MACE, major adverse cardiac event.
